Autor: "Habermann, TM" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Autorzy:: Personett HA; Department of Pharmacy, Mayo Clinic , Rochester , MN , USA.
Barreto EF; Department of Pharmacy, Mayo Clinic , Rochester , MN , USA.; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.
McCullough KB; Department of Pharmacy, Mayo Clinic , Rochester , MN , USA.
Dierkhising R; Division of Biomedical Statistics and Informatics, Mayo Clinic , Rochester , MN , USA.
Leung N; Division of Nephrology and Hypertension and Division of Hematology, Mayo Clinic , Rochester , MN , USA.; Division of Hematology, Mayo Clinic , Rochester , MN , USA.
Habermann TM; Division of Hematology, Mayo Clinic , Rochester , MN , USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2019 Sep; Vol. 60 (9), pp. 2271-2277. Date of Electronic Publication: 2019 Jun 21.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Acute Kidney Injury/*epidemiology
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Lymphoma/*drug therapy
Tumor Lysis Syndrome/*epidemiology
Urate Oxidase/*administration & dosage
Acute Kidney Injury/blood ; Acute Kidney Injury/etiology ; Acute Kidney Injury/prevention & control ; Aged ; Female ; Humans ; Incidence ; Lymphoma/blood ; Male ; Middle Aged ; Patient Admission/statistics & numerical data ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Tumor Lysis Syndrome/blood ; Tumor Lysis Syndrome/etiology ; Tumor Lysis Syndrome/prevention & control ; Uric Acid/antagonists & inhibitors ; Uric Acid/blood ; Uric Acid/toxicity

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
Autorzy:: Sonbol MB; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
Hilal T; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
Dueck AC; b Section of Biostatistics , Mayo Clinic , Scottsdale , AZ , USA.
Rosenthal AC; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
Conley CR; c Department of Laboratory Medicine and Pathology , Mayo Clinic , Scottsdale , AZ , USA.
Kosiorek HE; b Section of Biostatistics , Mayo Clinic , Scottsdale , AZ , USA.
Ginos BF; b Section of Biostatistics , Mayo Clinic , Scottsdale , AZ , USA.
Gano KM; d Cancer Clinical Research Office, Mayo Clinic , Phoenix , AZ , USA.
Nichols CS; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Leis JF; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
Johnston PB; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Habermann TM; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Northfelt DW; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
Bergsagel PL; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
Inwards DJ; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Witzig TE; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Ansell SM; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Reeder CB; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2018 Sep; Vol. 59 (9), pp. 2128-2134. Date of Electronic Publication: 2018 Jan 10.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Mantle-Cell/*drug therapy
Aged ; Aged, 80 and over ; Anemia/chemically induced ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Fatigue/chemically induced ; Female ; Humans ; Lymphoma, Mantle-Cell/pathology ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Survival Analysis ; Thrombocytopenia/chemically induced

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
Autorzy:: Morrison VA; a Division of Hematology, Oncology, and Transplantation , University of Minnesota and Hennepin County Medical Center , Minneapolis , MN , USA.; b Division of Infectious Disease , University of Minnesota , Minneapolis , MN , USA.
Weller EA; c Eastern Cooperative Oncology Group , Statistical Center , Boston , MA , USA.
Habermann TM; d Department of Medicine, Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Li S; c Eastern Cooperative Oncology Group , Statistical Center , Boston , MA , USA.
Fisher RI; e Wilmot Cancer Center , University of Rochester Medical Center , Rochester , NY , USA.
Cheson BD; f Division of Hematology , Lombardi Cancer Center, Georgetown University Hospital , Washington, DC , USA.
Peterson BA; g Division of Hematology, Oncology, and Transplantation , University of Minnesota , Minneapolis , MN , USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2017 Aug; Vol. 58 (8), pp. 1814-1822. Date of Electronic Publication: 2016 Dec 14.
Typ publikacji:: Clinical Trial; Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Colony-Stimulating Factors/*therapeutic use
Febrile Neutropenia/*drug therapy
Febrile Neutropenia/*etiology
Lymphoma, Large B-Cell, Diffuse/*complications
Age Factors ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived/adverse effects ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Colony-Stimulating Factors/administration & dosage ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Doxorubicin/adverse effects ; Doxorubicin/therapeutic use ; Febrile Neutropenia/diagnosis ; Febrile Neutropenia/epidemiology ; Female ; Humans ; Incidence ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; Neoplasm Staging ; Prednisone/adverse effects ; Prednisone/therapeutic use ; Retrospective Studies ; Risk Factors ; Rituximab ; Time Factors ; Treatment Outcome ; Vincristine/adverse effects ; Vincristine/therapeutic use
SCR Protocol:: CHOP protocol

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource.
Autorzy:: Wudhikarn K; a Department of Medicine , College of Medicine, University of Iowa , Iowa City , IA , USA.
Smith BJ; b Department of Biostatistics , College of Public Health, University of Iowa , Iowa City , IA , USA.; c Holden Comprehensive Cancer Center , Iowa City , IA , USA.
Button AM; b Department of Biostatistics , College of Public Health, University of Iowa , Iowa City , IA , USA.; c Holden Comprehensive Cancer Center , Iowa City , IA , USA.
Habermann TM; d Division of Hematology, Mayo Clinic , Rochester , MN , USA.
Thompson CA; d Division of Hematology, Mayo Clinic , Rochester , MN , USA.
Rosenstein LJ; a Department of Medicine , College of Medicine, University of Iowa , Iowa City , IA , USA.; c Holden Comprehensive Cancer Center , Iowa City , IA , USA.
Syrbu SI; e Department of Pathology , College of Medicine, University of Iowa , Iowa City , IA , USA.
Weiner GJ; a Department of Medicine , College of Medicine, University of Iowa , Iowa City , IA , USA.; c Holden Comprehensive Cancer Center , Iowa City , IA , USA.
Cerhan JR; f Division of Epidemiology, Mayo Clinic , Rochester , MN , USA.
Link BK; a Department of Medicine , College of Medicine, University of Iowa , Iowa City , IA , USA.; c Holden Comprehensive Cancer Center , Iowa City , IA , USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2015; Vol. 56 (8), pp. 2365-72. Date of Electronic Publication: 2015 Feb 09.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Follicular/*drug therapy
Lymphoma, Follicular/*epidemiology
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Female ; Humans ; Lymphatic Metastasis ; Lymphoma, Follicular/diagnosis ; Lymphoma, Follicular/mortality ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Prognosis ; Survival Analysis ; Treatment Outcome